home / stock / emmlf / emmlf news

EMMLF News and Press, OKYO Pharma Corp From 02/23/23

Stock Information
Company Name: OKYO Pharma Corp
Stock Symbol: EMMLF
Market: OTC
Menu
EMMLF EMMLF Quote EMMLF Short EMMLF News EMMLF Articles EMMLF Message Board
Get EMMLF Alerts

News, Short Squeeze, Breakout and More Instantly...
EMMLF - OKYO Pharma Announces Appointment of Dr. Jay S. Pepose to Its Scientific Advisory Board

LONDON and NEW YORK, Feb. 23, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announces the...
EMMLF - OKYO Pharma to Present at the Second Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on February 21-23, 2023.

LONDON and NEW YORK, Feb. 21, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) (“OKYO”, “OKYO Pharma” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to addre...

EMMLF - OKYO Pharma Limited Announces Closing of Public Offering and Nasdaq Listing

LONDON, May 19, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (“OKYO Pharma” or the “Company“), a life sciences company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, to...

EMMLF - OKYO Pharma Limited - PDMR Dealing

LONDON and NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announces that it has been notified tha...
EMMLF - OKYO Pharma Limited Announces Pricing of Initial Public Offering of ADSs in the U.S. with director participation

LONDON, May 17, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (" OKYO " or the " Company "), a life sciences company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases (“ DED ”) and ocular pai...

EMMLF - OKYO Pharma Limited Announces Pricing of Public Offering and Nasdaq Listing

LONDON, May 16, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (“OKYO Pharma” or the “Company“), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, an...

EMMLF - OKYO Pharma ("OKYO" or the "Company") - Announces Two Presentations at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

OK-101 ameliorates neuropathic corneal pain in a mouse model of ciliary nerve ligation BAM8-22 peptide analog OK-201 alleviates neuropathic corneal pain in mice LONDON, April 27, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology compan...
EMMLF - OKYO Pharma Limited ("OKYO" or the "Company") - OKYO publicly files a registration statement with the SEC for a proposed dual-listing on the Nasdaq Capital Market and Offering in the United States

LONDON, March 07, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF) (" OKYO " or the " Company "), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, is pleased to announce ...

EMMLF - OKYO Pharma ("OKYO" or the "Company") - announces issuance of U.S. Patent No. 11,254,720 covering OKYO's dry eye drug candidate OK-101 for use to treat ocular neuropathic pain

LONDON, Feb. 23, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announced that the patent entitled “Methods and S...

EMMLF - OKYO Pharma Limited ("OKYO" or the "Company") - Conversion of CLNs, cashless exercise of Warrants, and issue of equity

LONDON, Feb. 21, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, is pleased to announce that it has today issued 403,719,360 ne...
Previous 10 Next 10